Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: February 6, 2025 (Events reported on February 6, 2025; Press Release dated February 10, 2025)
Business Context: The Company is a biopharmaceutical firm developing CORDStrom, an investigational medicinal product for treating recessive dystrophic epidermolysis bullosa (RDEB) in pediatric patients.
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins). The following financial terms relate to specific agreements:
- Upfront Payment: Approximately $0.3 million (£250,000) payable within 30 days for a license agreement.
- Milestone Payment: Up to $7.5 million (£6,000,000) contingent upon the first marketing authorization granted by the FDA, EMA, or MHRA.
- Debt Status: No amounts were due or owed to Silicon Valley Bank (SVB) at the time of loan termination.
- Liquidity Impact: No early termination penalty was paid regarding the SVB loan agreement.
Material Changes
- New Licensing Agreement: Entered into an exclusive license agreement with Great Ormond Street Hospital NHS Foundation Trust (GOSH) for clinical trial data from the Mission EB study to support marketing authorization applications in the U.S., EU, and UK.
- Debt Termination: Terminated the Loan and Security Agreement dated June 10, 2021, with Silicon Valley Bank (SVB). The termination occurred with no outstanding balance and no penalty fees.
Outlook, Risks, and Contingencies
Management Commentary and Strategy: The Company intends to utilize the licensed data to prepare marketing authorization applications for CORDStrom for pediatric RDEB. The agreement includes patient access obligations, specifically sponsoring the supply of CORDStrom to UK patients in an open-label continuation study.
Risks and Contingencies:
- Termination Triggers: The License Agreement may be terminated by the Company if regulatory bodies (FDA, MHRA, EMA) deem Mission EB results insufficient for authorization, if reimbursement is refused by the National Health Service, or if manufacturing cannot be procured within 18 months due to events outside the Company's control.
- Surviving Obligations: Despite the loan termination, the Company remains bound by certain indemnification obligations under the former SVB Loan Agreement.
Investor Verification Checklist
- Verify the exact timing and amount of the £250,000 upfront payment to GOSH.
- Confirm the specific regulatory milestones required to trigger the £6,000,000 milestone payment.
- Review the full text of the License Agreement (Exhibit 10.1) for detailed patient access obligations and supply chain terms.
- Assess the impact of the 18-month manufacturing procurement deadline on the Company's operational timeline.
- Confirm that no hidden liabilities remain from the terminated SVB loan agreement beyond the stated indemnification obligations.